A Phase 1/2 interventional study of Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV) and Reference IPV in Poliomyelitis, sponsored by Takeda. Terminated at 4 sites in Panama. Open to participants aged 6 Weeks to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-31.
Sponsored by Takeda · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Poliomyelitis with a site in Panama — 2 open to participants now, 2 under way, none of them phase 3. Poliomyelitis · Panama.
Among the 10 studies in Poliomyelitis with a site in Panama, this one is the 8th largest by enrollment, is one of 3 that started in 2017, is the only one in phase 1/2, and was the 4th registered.
275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.
Browse Poliomyelitis studies →2 of the 10 studies in Poliomyelitis with a site in Panama are open now. Recruiting first, the newest first:
PATH · Sites in Panama
Ages 6 wk–7 wk · Healthy volunteers
PATH · Sites in Panama
Ages 1 days–4 yrs · Healthy volunteers
A study can be open while its sites in Panama have not opened yet or have stopped. Only those recruiting at a site in Panama →
Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 6 Weeks to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 3 · Phase 4 2
First in 2013; this study’s year is marked. 3 started in 2017.
This study's enrollment of 340 is below the median of 478 across 250 interventional studies indexed under Poliomyelitis.
Median enrollment 724 across the 10 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 6 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 1 study filed under Poliomyelitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Poliomyelitis with a site in Panama that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06895486PATHStudy of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation | 2026-12-28 |
| NCT05654467PATHStudy of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama | 2027-03-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Poliomyelitis with a site in Panama, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to select the optimal antigen dosage of the three Sabin poliovirus strains (types 1, 2, and 3) entering the composition of the stand-alone trivalent Sabin-based inactivated poliomyelitis vaccine (sIPV) to take forward into advanced stage studies. The selection will be carried out comparing the three sIPV study arms based on the safety and tolerability profile after each dose of primary immunization and the immune response to poliovirus types 1, 2, and 3 for both Sabin and Salk strains, after the final dose of a three dose primary immunization series (Day 85).
The vaccine being tested in this study is called sIPV. sIPV is used to prevent poliomyelitis. This study will look at the safety, tolerability of sIPV in healthy adults, toddlers and infants as well as safety and immunogenicity in toddlers and infants. .
The study will enroll approximately 340 participants including 40 adults, 60 toddlers and 240 infants. Adult participants will be randomly assigned to one of the two treatment groups-which will remain undisclosed to study doctor and participants during the study (unless there is an urgent medical need):
Toddler participants will be randomly assigned to one of the following treatment groups:
Infant participants will be randomly assigned to one of following treatment groups:
This is a multicentre trial. The overall time to participate in this study for adult is 8 days, for toddlers is 183 days and infants is 547 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult Lead-in Cohort
Toddler Lead-in Cohort
Infant Dose Ranging Cohort 1. Infants are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.
Exclusion Criteria:
Adult Lead-in Cohort
Toddler Lead-in Cohort
Infant Dose Ranging Cohort
All Cohorts
Known or suspected impairment/alteration of immune function, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sabin-based inactivated poliomyelitis vaccine (sIPV) containing 3, 100, and 100 D-Ag units (DU) of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
Placebo, intramuscular injection on Day 1.
Biological: sIPV Placebo
sIPV containing 3, 100, and 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
Reference IPV, intramuscular injection on Day 1.
Biological: Reference IPV
sIPV containing 0.75, 25, 25 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29, 57 and 365.
Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
sIPV containing 1.5, 50, 50 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
sIPV containing 3, 100, 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
Reference IPV, intramuscular injection on Days 1, 29 57 and 365.
Biological: Reference IPV
sIPV intramuscular injection
Reference IPV intramuscular injection
sIPV placebo-matching intramuscular injection
Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 1
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of the First Dose given on Day 1
Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 29
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of the Second Dose given on Day 29
Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 57
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 Days of the Third Dose given on Day 57
Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 1
Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of the First Dose given on Day 1
Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 29
Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of the Second Dose given on Day 29
Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 57
Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 Days of the Third Dose given on Day 57
Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV on Day 1
A systemic adverse event (AE) of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of the First Dose given on Day 1
Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV on Day 29
A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of the Second Dose given on Day 29
Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV on Day 57
A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of the Third Dose given on Day 57
Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort
An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.
Time frame: Within 28 days of primary vaccinations given on Days 1, 29 and 57 (Up to Day 85)
Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV Study Arms in Infant Dose Ranging Cohort
An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.
Time frame: Day 1 up to Day 547
Percentage of Participants With Seroconversion
Seroconversion is defined as i) initially seronegative infants (titer \<8 at Day 1) having a titer ≥8 at Day 85, or ii) initially seropositive infants (titer ≥8 at Day 1) with a 4-fold rise in antibody titers over the expected level of maternal antibodies at Day 85, calculated using a decline from the Day 1 titer with a half-life of 28 days.
Time frame: Day 85
Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV by Severity in Infant Dose Ranging Cohort
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (0-none, 1-mild: Minor reaction to touch, 2-moderate: Cries/protests on touch, 3-severe: Cries when limb is moved/spontaneously painful), erythema, induration and swelling (0: \<10 mm, 1-Mild: \>10 - ≤ 20 mm, 2-Moderate: \> 20 - ≤ 40 mm, 3-Severe: \> 40 mm). Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of primary vaccinations (First Dose given on Day 1, Second Dose given on Day 29, Third Dose given on Day 57)
Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV by Severity in Infant Dose Ranging Cohort
Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of primary vaccinations (First Dose given on Day 1, Second Dose given on Day 29, Third Dose given on Day 57)
Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV in Infant Dose Ranging Cohort
A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of primary vaccinations (First Dose given on Day 1, Second Dose given on Day 29, Third Dose given on Day 57)
Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV in Infant Dose Ranging Cohort
An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.
Time frame: Within 28 Days of primary vaccinations (Up to 85 days)
Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV or IPV Study Arms in Infant Dose Ranging Cohort
An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.
Time frame: Day 1 up to Day 547
Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (0-none, 1-mild: Minor reaction to touch, 2-moderate: Cries/protests on touch, 3-severe: Cries when limb is moved/spontaneously painful), erythema, induration and swelling (0: \<10 mm, 1-Mild: \>10 - ≤ 20 mm, 2-Moderate: \> 20 - ≤ 40 mm, 3-Severe: \> 40 mm).
Time frame: Within 7 days of booster vaccination given on Day 365
Percentage of Participants With Solicited Systemic AEs Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort
Percentage of participants with solicited systemic adverse events on a symptom by symptom basis, in each severity category will be reported. Solicited systemic adverse events include drowsiness, irritability/fussiness, loss of appetite, and fever. Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.
Time frame: Within 7 days of booster vaccination given on Day 365
Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort
Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.
Time frame: Within 7 days of booster vaccination given on Day 365
Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than SAEs) that occurred other than those that are solicited.
Time frame: Within 28 days of booster vaccination given on Day 365
Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort
Percentage of participants with solicited local reactions on a symptom by symptom basis, in each severity category will be reported. Solicited local reactions include pain, erythema, induration and swelling.
Time frame: Within 7 days of booster vaccination given on Day 365
Percentage of Participants With Solicited Systemic AEs Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort
Percentage of participants with solicited systemic adverse events on a symptom by symptom basis, in each severity category will be reported. Solicited systemic adverse events include headache, asthenia, malaise, arthralgia, myalgia.
Time frame: Within 7 days of booster vaccination given on Day 365
Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort
Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.
Time frame: Within 7 days of booster vaccination given on Day 365
Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort
An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.
Time frame: Within 28 Days of booster vaccination given on Day 365
Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in Toddler Lead-in Cohort
An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.
Time frame: Day 1 up to Day 183
Number of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm).
Time frame: Within 7 days of sIPV or placebo vaccination
Number of Participants With Solicited Systemic AEs Within 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort
Solicited systemic AEs were collected by participants within 7 days after vaccination and included headache, asthenia, malaise, arthralgia and myalgia and fever. Severity scales for headache were none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents normal activity with or without treatment. Severity scales for others were none, mild: no interference with daily activity, moderate: interference with daily activity and severe: prevents daily activity. Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of sIPV or placebo vaccination
Number of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort
A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each immunization. Data is only reported for those categories with at least 1 participant.
Time frame: Within 7 days of sIPV or placebo vaccination dose given on Day 1
Number of Participants Experiencing Non-serious Unsolicited AEs Within the 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort
An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.
Time frame: Within 7 days of sIPV or placebo vaccination
Number of Participants Experiencing SAEs Throughout the Entire Trial Duration in Adult Lead-in Cohort
An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.
Time frame: Day 1 up to Day 8
Seropositivity/Seroprotection Rate (SPR) on Days 85, 365 and 393 in Infant Dose Ranging Cohort
SPR is defined as the percentage of participants with antibodies titers of poliovirus types 1, 2, and 3 for both Sabin and Salk strain ≥8.
Time frame: Days 85, 365 and 393
Geometric Mean Titers (GMT) on Days 85, 365 and 393 in Infant Dose Ranging Cohort
GMT titers for poliovirus types 1, 2, and 3 for both Sabin and Salk strains will be reported.
Time frame: Days 85, 365 and 393
Vaccine Response Rate (VRR) on Day 393 in Infant Dose Ranging Cohort
VRR is defined as percentage of participants i) seronegative prior to booster vaccination (titer \<8) having a titer ≥8, or ii) seropositive prior to booster vaccination (titer ≥8) having a 4-fold rise in antibody titers.
Time frame: Day 393
Participants took part in the study at four investigative sites in Panama from 7 June 2017 to 18 October 2018.
| Milestone | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV |
|---|---|---|---|---|---|---|---|---|
| Started | 20 | 20 | 30 | 30 | 60 | 60 | 60 | 60 |
| Completed | 20 | 20 | 30 | 30 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 60 | 60 | 60 | 60 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal of consent | 0 | 0 | 0 | 0 | 4 | 12 | 6 | 4 |
| Withdrew: Study termination | 0 | 0 | 0 | 0 | 55 | 46 | 53 | 55 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose |
|---|---|---|---|
| Pain: First Dose (Day 1), Any | 84.2 | 69.2 | 80.4 |
| Pain: First Dose (Day 1), Mild | 26.3 | 30.8 | 41.1 |
| Pain: First Dose (Day 1), Moderate | 31.6 | 17.3 | 25.0 |
| Pain: First Dose (Day 1), Severe | 26.3 | 21.2 | 14.3 |
| Erythema: First Dose (Day 1), Any | 5.3 | 1.9 | 0 |
| Induration: First Dose (Day 1), Any | 1.8 | 3.9 | 0 |
| Induration: First Dose (Day 1), Moderate | 0 | 2.0 | 0 |
| Swelling: First Dose (Day 1), Any | 1.8 | 7.8 | 0 |
| Swelling: First Dose (Day 1), Moderate | 0 | 2.0 | 0 |
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose |
|---|---|---|---|
| Pain: Second Dose (Day 29), Any | 48.2 | 47.9 | 61.8 |
| Pain: Second Dose (Day 29), Mild | 30.4 | 25.0 | 36.4 |
| Pain: Second Dose (Day 29), Moderate | 14.3 | 16.7 | 18.2 |
| Pain: Second Dose (Day 29), Severe | 3.6 | 6.3 | 7.3 |
| Erythema: Second Dose (Day 29), Any | 1.8 | 2.1 | 0 |
| Induration: Second Dose (Day 29), Any | 0 | 2.1 | 0 |
| Swelling: Second Dose (Day 29), Any | 0 | 4.2 | 0 |
| Swelling: Second Dose (Day 29), Mild | 0 | 2.1 | 0 |
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose |
|---|---|---|---|
| Pain: Third Dose (Day 57), Any | 46.4 | 44.4 | 49.1 |
| Pain: Third Dose (Day 57), Mild | 33.9 | 31.1 | 34.0 |
| Pain: Third Dose (Day 57), Moderate | 8.9 | 8.9 | 11.3 |
| Pain: Third Dose (Day 57), Severe | 3.6 | 4.4 | 3.8 |
| Erythema: Third Dose (Day 57), Any | 0 | 2.2 | 1.9 |
| Swelling: Third Dose (Day 57), Any | 1.8 | 0 | 0 |
Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose |
|---|---|---|---|
| Drowsiness: First Dose (Day 1), Any | 49.1 | 48.1 | 47.3 |
| Drowsiness: First Dose (Day 1), Mild | 38.6 | 32.7 | 23.6 |
| Drowsiness: First Dose (Day 1), Moderate | 8.8 | 13.5 | 21.8 |
| Drowsiness: First Dose (Day 1), Severe | 1.8 | 1.9 | 1.8 |
| Irritability: First Dose (Day 1), Any | 56.1 | 57.7 | 58.2 |
| Irritability: First Dose (Day 1), Mild | 28.1 | 28.8 | 29.1 |
| Irritability: First Dose (Day 1), Moderate | 21.1 | 19.2 | 18.2 |
| Irritability: First Dose (Day 1), Severe | 7.0 | 9.6 | 10.9 |
| Loss of Appetite: First Dose (Day 1), Any | 29.8 | 25.0 | 21.8 |
| Loss of Appetite: First Dose (Day 1), Mild | 26.3 | 23.1 | 9.1 |
| Loss of Appetite: First Dose (Day 1), Moderate | 3.5 | 1.9 | 12.7 |
Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose |
|---|---|---|---|
| Drowsiness: Second Dose (Day 29), Any | 30.4 | 20.8 | 36.4 |
| Drowsiness: Second Dose (Day 29), Mild | 19.6 | 18.8 | 25.5 |
| Drowsiness: Second Dose (Day 29), Moderate | 10.7 | 2.1 | 10.9 |
| Irritability: Second Dose (Day 29), Any | 37.5 | 33.3 | 45.5 |
| Irritability: Second Dose (Day 29), Mild | 19.6 | 25.0 | 30.9 |
| Irritability: Second Dose (Day 29), Moderate | 10.7 | 6.3 | 9.1 |
| Irritability: Second Dose (Day 29), Severe | 7.1 | 2.1 | 5.5 |
| Loss of Appetite: Second Dose (Day 29), Any | 14.3 | 10.4 | 18.2 |
| Loss of Appetite: Second Dose (Day 29), Mild | 12.5 | 8.3 | 16.4 |
| Loss of Appetite: Second Dose (Day 29), Moderate | 1.8 | 2.1 | 0 |
| Loss of Appetite: Second Dose (Day 29), Severe | 0 | 0 | 1.8 |
Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose |
|---|---|---|---|
| Drowsiness: Third Dose (Day 57), Any | 38.2 | 21.7 | 32.1 |
| Drowsiness: Third Dose (Day 57), Mild | 25.5 | 21.7 | 26.4 |
| Drowsiness: Third Dose (Day 57), Moderate | 12.7 | 0 | 5.7 |
| Irritability: Third Dose (Day 57), Any | 40.0 | 26.1 | 37.7 |
| Irritability: Third Dose (Day 57), Mild | 27.3 | 21.7 | 28.3 |
| Irritability: Third Dose (Day 57), Moderate | 5.5 | 2.2 | 7.5 |
| Irritability: Third Dose (Day 57), Severe | 7.3 | 2.2 | 1.9 |
| Loss of Appetite: Third Dose (Day 57), Any | 10.9 | 6.5 | 13.2 |
| Loss of Appetite: Third Dose (Day 57), Mild | 9.1 | 6.5 | 13.2 |
| Loss of Appetite: Third Dose (Day 57), Moderate | 1.8 | 0 | 0 |
A systemic adverse event (AE) of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose |
|---|---|---|---|
| Fever: First Dose (Day 1), Any | 15.8 | 17.3 | 23.6 |
| Fever: First Dose (Day 1), 38.0°C - 38.4°C | 8.8 | 9.6 | 14.5 |
| Fever: First Dose (Day 1), 38.5°C - 38.9°C | 7.0 | 7.7 | 9.1 |
A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose |
|---|---|---|---|
| Fever: Second Dose (Day 29), Any | 7.1 | 6.4 | 14.8 |
| Fever: Second Dose (Day 29), 38.0°C - 38.4°C | 3.6 | 2.1 | 11.1 |
| Fever: Second Dose (Day 29), 38.5°C - 38.9°C | 3.6 | 2.1 | 3.7 |
| Fever: Second Dose (Day 29), 39.0°C - 39.4°C | 0 | 2.1 | 0 |
A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose |
|---|---|---|---|
| Fever: Third Dose (Day 57), Any | 9.1 | 8.7 | 15.4 |
| Fever: Third Dose (Day 57), 38.0°C - 38.4°C | 9.1 | 6.5 | 3.8 |
| Fever: Third Dose (Day 57), 38.5°C - 38.9°C | 0 | 0 | 7.7 |
| Fever: Third Dose (Day 57), 39.0°C - 39.4°C | 0 | 2.2 | 1.9 |
| Fever: Third Dose (Day 57), 39.5°C - 39.9°C | 0 | 0 | 1.9 |
An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose |
|---|---|---|---|
| Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort | 28.8 | 28.3 | 31.7 |
An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose |
|---|---|---|---|
| Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV Study Arms in Infant Dose Ranging Cohort | 13.6 | 8.3 | 8.3 |
Seroconversion is defined as i) initially seronegative infants (titer \<8 at Day 1) having a titer ≥8 at Day 85, or ii) initially seropositive infants (titer ≥8 at Day 1) with a 4-fold rise in antibody titers over the expected level of maternal antibodies at Day 85, calculated using a decline from the Day 1 titer with a half-life of 28 days.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV |
|---|---|---|---|---|
| Sabin Type 1: Day 85 | 63.0 (48.7 to 75.7) | 77.8 (62.9 to 88.8) | 86.0 (73.3 to 94.2) | 92.5 (81.8 to 97.9) |
| Sabin Type 2: Day 85 | 68.5 (54.4 to 80.5) | 77.8 (62.9 to 88.8) | 90.0 (78.2 to 96.7) | 94.3 (84.3 to 98.8) |
| Sabin Type 3, Day 85 | 96.3 (87.3 to 99.5) | 100 (92.1 to 100) | 96.0 (86.3 to 99.5) | 96.2 (87.0 to 99.5) |
| Salk Type 1: Day 85 | 37.0 (24.3 to 51.3) | 53.3 (37.9 to 68.3) | 68.0 (53.3 to 80.5) | 96.2 (87.0 to 99.5) |
| Salk Type 2: Day 85 | 35.2 (22.7 to 49.4) | 55.6 (40.0 to 70.4) | 70.0 (55.4 to 82.1) | 96.2 (87.0 to 99.5) |
| Salk Type 3: Day 85 | 90.7 (79.7 to 96.9) | 93.3 (81.7 to 98.6) | 94.0 (83.5 to 98.7) | 94.3 (84.3 to 98.8) |
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (0-none, 1-mild: Minor reaction to touch, 2-moderate: Cries/protests on touch, 3-severe: Cries when limb is moved/spontaneously painful), erythema, induration and swelling (0: \<10 mm, 1-Mild: \>10 - ≤ 20 mm, 2-Moderate: \> 20 - ≤ 40 mm, 3-Severe: \> 40 mm). Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV |
|---|---|---|---|---|
| Pain: First Dose (Day 1), Any | 84.2 | 69.2 | 80.4 | 86.0 |
| Pain: First Dose (Day 1), Mild | 26.3 | 30.8 | 41.1 | 22.8 |
| Pain: First Dose (Day 1), Moderate | 31.6 | 17.3 | 25.0 | 40.4 |
| Pain: First Dose (Day 1), Severe | 26.3 | 21.2 | 14.3 | 22.8 |
| Erythema: First Dose (Day 1), Any | 5.3 | 1.9 | 0 | 1.8 |
| Induration: First Dose (Day 1), Any | 1.8 | 3.9 | 0 | 1.8 |
| Induration: First Dose (Day 1), Moderate | 0 | 2.0 | 0 | 0 |
| Swelling: First Dose (Day 1), Any | 1.8 | 7.8 | 0 | 1.8 |
| Swelling: First Dose (Day 1), Moderate | 0 | 2.0 | 0 | 0 |
| Pain: Second Dose (Day 29), Any | 48.2 | 47.9 | 61.8 | 59.6 |
| Pain: Second Dose (Day 29), Mild | 30.4 | 25.0 | 36.4 | 45.6 |
| Pain: Second Dose (Day 29), Moderate | 14.3 | 16.7 | 18.2 | 8.8 |
| Pain: Second Dose (Day 29), Severe | 3.6 | 6.3 | 7.3 | 5.3 |
| Erythema: Second Dose (Day 29), Any | 1.8 | 2.1 | 0 | 0 |
| Induration: Second Dose (Day 29), Any | 0 | 2.1 | 0 | 0 |
| Swelling: Second Dose (Day 29), Any | 0 | 4.2 | 0 | 0 |
| Swelling: Second Dose (Day 29), Mild | 0 | 2.1 | 0 | 0 |
| Pain: Third Dose (Day 57), Any | 46.4 | 44.4 | 49.1 | 60.7 |
| Pain: Third Dose (Day 57), Mild | 33.9 | 31.1 | 34.0 | 48.2 |
| Pain: Third Dose (Day 57), Moderate | 8.9 | 8.9 | 11.3 | 8.9 |
| Pain: Third Dose (Day 57), Severe | 3.6 | 4.4 | 3.8 | 3.6 |
| Erythema: Third Dose (Day 57), Any | 0 | 2.2 | 1.9 | 1.8 |
| Induration: Third Dose (Day 57), Any | 0 | 0 | 0 | 1.8 |
| Swelling: Third Dose (Day 57), Any | 1.8 | 0 | 0 | 0 |
Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV |
|---|---|---|---|---|
| Drowsiness: First Dose (Day 1), Any | 49.1 | 48.1 | 47.3 | 44.6 |
| Drowsiness: First Dose (Day 1), Mild | 38.6 | 32.7 | 23.6 | 26.8 |
| Drowsiness: First Dose (Day 1), Moderate | 8.8 | 13.5 | 21.8 | 16.1 |
| Drowsiness: First Dose (Day 1), Severe | 1.8 | 1.9 | 1.8 | 1.8 |
| Irritability: First Dose (Day 1), Any | 56.1 | 57.7 | 58.2 | 61.4 |
| Irritability: First Dose (Day 1), Mild | 28.1 | 28.8 | 29.1 | 28.1 |
| Irritability: First Dose (Day 1), Moderate | 21.1 | 19.2 | 18.2 | 22.8 |
| Irritability: First Dose (Day 1), Severe | 7.0 | 9.6 | 10.9 | 10.5 |
| Loss of Appetite: First Dose (Day 1), Any | 29.8 | 25.0 | 21.8 | 19.3 |
| Loss of Appetite: First Dose (Day 1), Mild | 26.3 | 23.1 | 9.1 | 8.8 |
| Loss of Appetite: First Dose (Day 1), Moderate | 3.5 | 1.9 | 12.7 | 10.5 |
| Drowsiness: Second Dose (Day 29), Any | 30.4 | 20.8 | 36.4 | 29.8 |
| Drowsiness: Second Dose (Day 29), Mild | 19.6 | 18.8 | 25.5 | 22.8 |
| Drowsiness: Second Dose (Day 29), Moderate | 10.7 | 2.1 | 10.9 | 7.0 |
| Irritability: Second Dose (Day 29), Any | 37.5 | 33.3 | 45.5 | 38.6 |
| Irritability: Second Dose (Day 29), Mild | 19.6 | 25.0 | 30.9 | 26.3 |
| Irritability: Second Dose (Day 29), Moderate | 10.7 | 6.3 | 9.1 | 8.8 |
| Irritability: Second Dose (Day 29), Severe | 7.1 | 2.1 | 5.5 | 3.5 |
| Loss of Appetite: Second Dose (Day 29), Any | 14.3 | 10.4 | 18.2 | 8.8 |
| Loss of Appetite: Second Dose (Day 29), Mild | 12.5 | 8.3 | 16.4 | 8.8 |
| Loss of Appetite: Second Dose (Day 29), Moderate | 1.8 | 2.1 | 0 | 0 |
| Loss of Appetite: Second Dose (Day 29), Severe | 0 | 0 | 1.8 | 0 |
| Drowsiness: Third Dose (Day 57), Any | 38.2 | 21.7 | 32.1 | 25.0 |
| Drowsiness: Third Dose (Day 57), Mild | 25.5 | 21.7 | 26.4 | 16.1 |
| Drowsiness: Third Dose (Day 57), Moderate | 12.7 | 0 | 5.7 | 8.9 |
| Irritability: Third Dose (Day 57), Any | 40.0 | 26.1 | 37.7 | 33.9 |
| Irritability: Third Dose (Day 57), Mild | 27.3 | 21.7 | 28.3 | 26.8 |
| Irritability: Third Dose (Day 57), Moderate | 5.5 | 2.2 | 7.5 | 7.1 |
| Irritability: Third Dose (Day 57), Severe | 7.3 | 2.2 | 1.9 | 0 |
| Loss of Appetite: Third Dose (Day 57), Any | 10.9 | 6.5 | 13.2 | 8.9 |
| Loss of Appetite: Third Dose (Day 57), Mild | 9.1 | 6.5 | 13.2 | 3.6 |
| Loss of Appetite: Third Dose (Day 57), Moderate | 1.8 | 0 | 0 | 3.6 |
| Loss of Appetite: Third Dose (Day 57), Severe | 0 | 0 | 0 | 1.8 |
A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV |
|---|---|---|---|---|
| Fever: First Dose (Day 1), Any | 15.8 | 17.3 | 23.6 | 33.3 |
| Fever: First Dose (Day 1), 38.0°C - 38.4°C | 8.8 | 9.6 | 14.5 | 15.8 |
| Fever: First Dose (Day 1), 38.5°C - 38.9°C | 7.0 | 7.7 | 9.1 | 15.8 |
| Fever: First Dose (Day 1), >= 40.0°C | 0 | 0 | 0 | 1.8 |
| Fever: Second Dose (Day 29), Any | 7.1 | 6.4 | 14.8 | 10.5 |
| Fever: Second Dose (Day 29), 38.0°C - 38.4°C | 3.6 | 2.1 | 11.1 | 7.0 |
| Fever: Second Dose (Day 29), 38.5°C - 38.9°C | 3.6 | 2.1 | 3.7 | 3.5 |
| Fever: Second Dose (Day 29), 39.0°C - 39.4°C | 0 | 2.1 | 0 | 0 |
| Fever: Third Dose (Day 57), Any | 9.1 | 8.7 | 15.4 | 12.5 |
| Fever: Third Dose (Day 57), 38.0°C - 38.4°C | 9.1 | 6.5 | 3.8 | 7.1 |
| Fever: Third Dose (Day 57), 38.5°C - 38.9°C | 0 | 0 | 7.7 | 5.4 |
| Fever: Third Dose (Day 57), 39.0°C - 39.4°C | 0 | 2.2 | 1.9 | 0 |
| Fever: Third Dose (Day 57), 39.5°C - 39.9°C | 0 | 0 | 1.9 | 0 |
An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV |
|---|---|---|---|---|
| Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV in Infant Dose Ranging Cohort | 28.8 | 28.3 | 31.7 | 33.3 |
An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV |
|---|---|---|---|---|
| Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV or IPV Study Arms in Infant Dose Ranging Cohort | 13.6 | 8.3 | 8.3 | 13.3 |
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (0-none, 1-mild: Minor reaction to touch, 2-moderate: Cries/protests on touch, 3-severe: Cries when limb is moved/spontaneously painful), erythema, induration and swelling (0: \<10 mm, 1-Mild: \>10 - ≤ 20 mm, 2-Moderate: \> 20 - ≤ 40 mm, 3-Severe: \> 40 mm).
No measurements were reported for this outcome.
Percentage of participants with solicited systemic adverse events on a symptom by symptom basis, in each severity category will be reported. Solicited systemic adverse events include drowsiness, irritability/fussiness, loss of appetite, and fever. Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.
No measurements were reported for this outcome.
Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.
No measurements were reported for this outcome.
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than SAEs) that occurred other than those that are solicited.
No measurements were reported for this outcome.
Percentage of participants with solicited local reactions on a symptom by symptom basis, in each severity category will be reported. Solicited local reactions include pain, erythema, induration and swelling.
No measurements were reported for this outcome.
Percentage of participants with solicited systemic adverse events on a symptom by symptom basis, in each severity category will be reported. Solicited systemic adverse events include headache, asthenia, malaise, arthralgia, myalgia.
No measurements were reported for this outcome.
Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.
No measurements were reported for this outcome.
An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.
No measurements were reported for this outcome.
An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.
| percentage of participants | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV |
|---|---|---|
| Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in Toddler Lead-in Cohort | 0 | 0 |
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm).
| Participants | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo |
|---|---|---|
| Pain: First Dose (Day 1), Any | 9 | 4 |
| Pain: First Dose (Day 1), Mild | 7 | 4 |
| Pain: First Dose (Day 1), Moderate | 2 | 0 |
| Erythema: First Dose (Day 1), Any | 1 | 0 |
| Induration: First Dose (Day 1), Any | 0 | 1 |
| Induration: First Dose (Day 1), Mild | 0 | 1 |
| Swelling: First Dose (Day 1), Any | 0 | 1 |
| Swelling: First Dose (Day 1), Mild | 0 | 1 |
Solicited systemic AEs were collected by participants within 7 days after vaccination and included headache, asthenia, malaise, arthralgia and myalgia and fever. Severity scales for headache were none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents normal activity with or without treatment. Severity scales for others were none, mild: no interference with daily activity, moderate: interference with daily activity and severe: prevents daily activity. Data is only reported for those categories with at least 1 participant.
| Participants | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo |
|---|---|---|
| Headache: First Dose (Day 1), Any | 3 | 3 |
| Headache: First Dose (Day 1), Mild | 1 | 3 |
| Headache: First Dose (Day 1), Moderate | 1 | 0 |
| Headache: First Dose (Day 1), Severe | 1 | 0 |
| Malaise: First Dose (Day 1), Any | 1 | 1 |
| Malaise: First Dose (Day 1), Mild | 0 | 1 |
| Malaise: First Dose (Day 1), Moderate | 1 | 0 |
| Arthralgia: First Dose (Day 1), Any | 4 | 3 |
| Arthralgia: First Dose (Day 1), Mild | 2 | 1 |
| Myalgia: First Dose (Day 1), Any | 4 | 3 |
| Myalgia: First Dose (Day 1), Mild | 2 | 2 |
| Myalgia: First Dose (Day 1), Moderate | 2 | 1 |
A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each immunization. Data is only reported for those categories with at least 1 participant.
| Participants | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo |
|---|---|---|
| Fever: First Dose (Day 1), Any | 0 | 1 |
| Fever: First Dose (Day 1), 38.5°C - 38.9°C | 0 | 1 |
An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.
| Participants | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo |
|---|---|---|
| Number of Participants Experiencing Non-serious Unsolicited AEs Within the 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort | 0 | 0 |
An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.
| Participants | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo |
|---|---|---|
| Number of Participants Experiencing SAEs Throughout the Entire Trial Duration in Adult Lead-in Cohort | 0 | 0 |
SPR is defined as the percentage of participants with antibodies titers of poliovirus types 1, 2, and 3 for both Sabin and Salk strain ≥8.
| percentage of participants | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV |
|---|---|---|---|---|
| Sabin Type 1: Day 85 | 72.2 (58.4 to 83.5) | 89.1 (76.4 to 96.4) | 88.0 (75.7 to 95.5) | 96.2 (87.0 to 99.5) |
| Sabin Type 2: Day 85 | 83.3 (70.7 to 92.1) | 95.7 (85.2 to 99.5) | 100 (92.9 to 100) | 98.1 (89.9 to 100) |
| Sabin Type 3: Day 85 | 98.1 (90.1 to 100) | 100 (92.3 to 100) | 98.0 (89.4 to 99.9) | 100 (93.3 to 100) |
| Salk Type 1: Day 85 | 42.6 (29.2 to 56.8) | 56.5 (41.1 to 71.1) | 72.0 (57.5 to 83.8) | 96.2 (87.0 to 99.5) |
| Salk Type 2: Day 85 | 38.9 (25.9 to 53.1) | 65.2 (49.8 to 78.6) | 74.0 (59.7 to 85.4) | 100 (93.3 to 100) |
| Salk Type 3: Day 85 | 92.6 (82.1 to 97.9) | 93.5 (82.1 to 98.6) | 96.0 (86.3 to 99.5) | 98.1 (89.9 to 100) |
GMT titers for poliovirus types 1, 2, and 3 for both Sabin and Salk strains will be reported.
| titer | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV |
|---|---|---|---|---|
| Sabin Type 1: Day 85 | 47.2 (28.2 to 78.8) | 105.6 (61.8 to 180.4) | 222.7 (130.6 to 379.7) | 155.0 (104.4 to 230.3) |
| Sabin Type 2: Day 85 | 53.2 (34.4 to 82.3) | 119.7 (74.2 to 192.9) | 205.1 (138.9 to 303.0) | 268.1 (188.4 to 381.5) |
| Sabin Type 3: Day 85 | 400.0 (267.3 to 598.4) | 748.2 (540.5 to 1035.7) | 844.6 (598.2 to 1192.5) | 533.8 (391.8 to 727.1) |
| Salk Type 1: Day 85 | 11.7 (8.6 to 15.7) | 18.2 (11.5 to 28.9) | 27.5 (17.8 to 42.6) | 719.4 (520.9 to 993.7) |
| Salk Type 2: Day 85 | 14.3 (9.7 to 21.2) | 22.4 (14.8 to 33.9) | 26.2 (18.2 to 37.6) | 400.1 (296.7 to 539.7) |
| Salk Type 3: Day 85 | 139.7 (83.7 to 233.2) | 257.9 (160.0 to 415.6) | 361.2 (230.4 to 566.2) | 456.2 (317.3 to 656.0) |
VRR is defined as percentage of participants i) seronegative prior to booster vaccination (titer \<8) having a titer ≥8, or ii) seropositive prior to booster vaccination (titer ≥8) having a 4-fold rise in antibody titers.
No measurements were reported for this outcome.
Collected over Up to Day 8 for Adults, Day 183 for Toddlers and Day 597 for Infants. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adult Lead-in Cohort: sIPV High Dose | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Adult Lead-in Cohort: Placebo | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Toddler Lead-in Cohort: sIPV High Dose | 0/30 (0%) | 0/30 (0%) | 8/30 (26.7%) |
| Toddler Lead-in Cohort: Reference IPV | 0/30 (0%) | 0/30 (0%) | 13/30 (43.3%) |
| Infant Dose Ranging Cohort: sIPV Low Dose | 0/59 (0%) | 8/59 (13.6%) | 17/59 (28.8%) |
| Infant Dose Ranging Cohort: sIPV Medium Dose | 1/60 (1.7%) | 5/60 (8.3%) | 17/60 (28.3%) |
| Infant Dose Ranging Cohort: sIPV High Dose | 0/60 (0%) | 5/60 (8.3%) | 19/60 (31.7%) |
| Infant Dose Ranging Cohort: Reference IPV | 1/60 (1.7%) | 8/60 (13.3%) | 20/60 (33.3%) |
| Event | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV |
|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/20 | 0/20 | 0/30 | 0/30 | 1/59 | 4/60 | 3/60 | 2/60 |
| GastroenteritisInfections and infestations | 0/20 | 0/20 | 0/30 | 0/30 | 2/59 | 0/60 | 0/60 | 0/60 |
| BronchiolitisInfections and infestations | 0/20 | 0/20 | 0/30 | 0/30 | 1/59 | 0/60 | 1/60 | 2/60 |
| BronchitisInfections and infestations | 0/20 | 0/20 | 0/30 | 0/30 | 1/59 | 0/60 | 0/60 | 0/60 |
| Urinary tract infectionInfections and infestations | 0/20 | 0/20 | 0/30 | 0/30 | 1/59 | 0/60 | 0/60 | 0/60 |
| Milk allergyImmune system disorders | 0/20 | 0/20 | 0/30 | 0/30 | 1/59 | 0/60 | 0/60 | 0/60 |
| TracheitisInfections and infestations | 0/20 | 0/20 | 0/30 | 0/30 | 1/59 | 0/60 | 0/60 | 0/60 |
| Meningitis asepticInfections and infestations | 0/20 | 0/20 | 0/30 | 0/30 | 0/59 | 0/60 | 0/60 | 1/60 |
| CyanosisCardiac disorders | 0/20 | 0/20 | 0/30 | 0/30 | 0/59 | 0/60 | 1/60 | 0/60 |
| DeathGeneral disorders | 0/20 | 0/20 | 0/30 | 0/30 | 0/59 | 1/60 | 0/60 | 0/60 |
| Event | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/20 | 0/20 | 5/30 | 8/30 | 9/59 | 9/60 | 13/60 | 13/60 |
| TonsillitisInfections and infestations | 0/20 | 0/20 | 0/30 | 0/30 | 7/59 | 7/60 | 4/60 | 5/60 |
| InfluenzaInfections and infestations | 0/20 | 0/20 | 2/30 | 3/30 | 0/59 | 0/60 | 0/60 | 0/60 |
| RhinitisInfections and infestations | 0/20 | 0/20 | 0/30 | 0/30 | 4/59 | 3/60 | 3/60 | 3/60 |
| PyrexiaGeneral disorders | 0/20 | 0/20 | 1/30 | 2/30 | 0/59 | 0/60 | 0/60 | 0/60 |
All randomized participants.
| Age, Continuous(years) | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 34.9 ± 8.56 | 35.1 ± 8.23 | — | — | — | — | — | — | 35.0 ± 8.29 |
| Age, Continuous(months) | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | — | — | 14.1 ± 0.98 | 14.0 ± 1.02 | — | — | — | — | 14.0 ± 0.99 |
| Age, Continuous(weeks) | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | 6.6 ± 0.67 | 6.5 ± 0.62 | 6.5 ± 0.68 | 6.5 ± 0.62 | 6.5 ± 0.65 |
| Sex: Female, Male(Participants) | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 16 | 13 | 13 | 12 | 31 | 33 | 29 | 22 | 169 |
| Male | 4 | 7 | 17 | 18 | 29 | 27 | 31 | 38 | 171 |
| Race (NIH/OMB)(Participants) | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 18 | 13 | 29 | 29 | 58 | 57 | 55 | 58 | 317 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 6 | 1 | 1 | 1 | 2 | 2 | 2 | 16 |
| White | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 6 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Panama | 20 | 20 | 30 | 30 | 60 | 60 | 60 | 60 | 340 |
| Height(centimeter (cm)) | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 160.00 (147.0 to 178.0) | 161.45 (149.0 to 189.0) | 77.13 (72.0 to 85.0) | 76.53 (70.0 to 80.0) | 55.71 (35.8 to 63.0) | 56.29 (52.0 to 72.0) | 55.21 (36.3 to 60.0) | 56.21 (51.0 to 75.0) | 87.31 (51.0 to 189.0) |
| Weight(kilogram (kg)) | Adult Lead-in Cohort: sIPV High Dose | Adult Lead-in Cohort: Placebo | Toddler Lead-in Cohort: sIPV High Dose | Toddler Lead-in Cohort: Reference IPV | Infant Dose Ranging Cohort: sIPV Low Dose | Infant Dose Ranging Cohort: sIPV Medium Dose | Infant Dose Ranging Cohort: sIPV High Dose | Infant Dose Ranging Cohort: Reference IPV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 74.30 (56.5 to 100.0) | 68.74 (41.5 to 98.0) | 10.21 (8.4 to 12.5) | 10.32 (7.5 to 15.3) | 4.94 (3.7 to 6.6) | 4.94 (3.4 to 6.1) | 4.89 (3.6 to 6.3) | 4.98 (3.2 to 5.9) | 22.91 (3.2 to 100.0) |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Jun 2017 to primary completion in Apr 2018, 9 months.
Results were first posted in Jan 2020, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.